- Home
- MKZR vs NEUP Comparison
MKZR vs NEUP Comparison
Compare MKZR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- NEUP
- Stock Information
- Founded
- MKZR 2012
- NEUP 1996
- Country
- MKZR United States
- NEUP United States
- Employees
- MKZR N/A
- NEUP N/A
- Industry
- MKZR
- NEUP
- Sector
- MKZR
- NEUP
- Exchange
- MKZR Nasdaq
- NEUP Nasdaq
- Market Cap
- MKZR 10.3M
- NEUP 10.3M
- IPO Year
- MKZR N/A
- NEUP N/A
- Fundamental
- Price
- MKZR $4.20
- NEUP $4.55
- Analyst Decision
- MKZR
- NEUP Strong Buy
- Analyst Count
- MKZR 0
- NEUP 2
- Target Price
- MKZR N/A
- NEUP $28.00
- AVG Volume (30 Days)
- MKZR 32.1K
- NEUP 229.1K
- Earning Date
- MKZR 11-14-2025
- NEUP 11-14-2025
- Dividend Yield
- MKZR 24.69%
- NEUP N/A
- EPS Growth
- MKZR N/A
- NEUP N/A
- EPS
- MKZR N/A
- NEUP N/A
- Revenue
- MKZR $20,994,778.00
- NEUP $15,649,448.00
- Revenue This Year
- MKZR N/A
- NEUP N/A
- Revenue Next Year
- MKZR N/A
- NEUP N/A
- P/E Ratio
- MKZR N/A
- NEUP N/A
- Revenue Growth
- MKZR 3.63
- NEUP N/A
- 52 Week Low
- MKZR $3.86
- NEUP $2.90
- 52 Week High
- MKZR $50.00
- NEUP $21.40
- Technical
- Relative Strength Index (RSI)
- MKZR 38.42
- NEUP 37.91
- Support Level
- MKZR $3.92
- NEUP $4.13
- Resistance Level
- MKZR $4.86
- NEUP $4.59
- Average True Range (ATR)
- MKZR 0.41
- NEUP 0.38
- MACD
- MKZR -0.05
- NEUP 0.30
- Stochastic Oscillator
- MKZR 20.88
- NEUP 34.29
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.